Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ben Davis

Hello, everyone. My name is Ben Davis. I’m an associate with the JPMorgan Healthcare Investment Banking team, and I hope you’re all enjoying your third day of the 2026 JPMorgan Healthcare Conference. It’s my privilege to introduce Liquidia team. CEO, Roger Jeffs, will be presenting. Afterwards, he’ll be joined by CFO, Michael Kaseta, on stage for a Q&A at the end.

Roger Jeffs
CEO & Director

Great. Thank you, Ben, and thank you for all of you here today. Also, thank you to those online who are listening in. I’m going to give the corporate overview really to give you a sense of kind of how we did in 2025. As a preview to that, we had a spectacular year, and also then give you a look into the future, kind of where we’re headed above and beyond where we are today.

Also, I want to say that I’m joined here today with Rusty Schundler, our General Counsel; Scott Moomaw, our Chief Commercial Officer; Jason Adair, our Chief Business Officer; and Rajeev Saggar, our Chief Medical Officer. Usual forward-looking statements, and I’ll refer you to our SEC filings for the true risks and uncertainties.

So for those of you who may be new to the story, Liquidia is a biopharmaceutical company driven by science and passion with patients as our North Star. And our purpose is to improve inhaled drug delivery to by employing proprietary and better formulations to focus on particularly the prostacyclin class of therapeutics to change and improve the standard of care for patients with high unmet need.

What